TORL-3-600 / TORL Biotherap - LARVOL DELTA

GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer (AACR-NCI-EORTC 2025) - "These preclinical data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."

Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5

First in Human Study of TORL-3-600 in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=70 | Active, not recruiting | Sponsor: TORL Biotherapeutics, LLC | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Jun 2026

Enrollment closed • First-in-human • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline (PRNewswire) - "Proceeds from this Series B-2 financing will be used to continue the clinical development of TORL-1-23, the Company's first-in-class ADC to treat CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial that will start in the second half of 2024....Proceeds will also be used to fund the on-going Phase 1 studies for the TORL-2-307 program, both a monoclonal antibody (mAb) and an ADC, for the treatment of CLDN 18.2+ solid tumors, TORL-3-600, an ADC for the treatment of CDH17+ colorectal cancer, and TORL-4-500, an ADC for the treatment of Delta like non-canonical Notch Ligand 1 (DLK1) positive solid tumors."

Financing • New P1 trial • New P2 trial • Colorectal Cancer • Gastroesophageal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor